NANO Nuclear Announces Opening Keynote Presentation and Platinum Sponsorship at the Upcoming Reuters Events: SMR & Advanced Reactor 2025 Conference
NANO Nuclear Energy Chief Executive Officer James Walker will lead the opening keynote presentation titled, 'The Growth of U.S. Advanced Reactors -- Wall Street's Success Story' at 9:00am on May 12 th. In the presentation, he will explore how U.S. policy shifts, global energy demand, and the availability of clean energy focused investment capital are hastening the commercialization of advanced nuclear reactors, including small nuclear reactors (known as SMRs) like those being developed by NANO Nuclear, and how NANO Nuclear capitalized on these trends to become the best performing initial public offering in the U.S. of 2024.
'Reuters Events offer a valuable opportunity to engage with stakeholders and leading innovators in the SMR and advanced reactor field,' said James Walker, Chief Executive Officer of NANO Nuclear. 'I'm excited for NANO Nuclear to be the leading sponsor and to personally participate in this year's conference to discuss NANO Nuclear's journey and mission, and gain insights from the broader community shaping the future of nuclear technology.'
Reuters Events: SMR & Advanced Reactor 2025 is the only senior-level meeting point for the SMR community, where 600+ leaders from utilities, financiers, reactor developers, technology providers and regulators unite to create meaningful connections, share trusted insights, and obtain lessons-learned to inform your multi-billion-dollar strategy at pace.
'This conference unites some of the most forward-thinking innovators in the advanced reactor space,' said Professor Massimiliano Fratoni, Senior Director and Head of Reactor Design of NANO Nuclear. 'It's an excellent forum to learn about the direction of the nuclear industry and exchange ideas with those driving progress. I'm looking forward to the informative sessions on offer.'
'NANO Nuclear is executing on schedule, and we expect the next 12 months to include several important regulatory and operational milestones that will help secure our leadership in the U.S. microreactor race,' said Jay Yu, Founder and Chairman of NANO Nuclear. 'The achievement of these milestones would be key as we advance toward construction, demonstration, regulatory licensing and eventual commercialization and deployment for our cutting-edge reactors. I look forward to discussing our progress with investors and industry peers at the upcoming Reuters SMR & Advanced Reactor Conference.'
A replay of Mr. Walker's presentation if produced by Reuters Events: SMR & Advanced Reactor 2025 will be available on NANO Nuclear's website for at least 30 days following the presentation at https://ir.nanonuclearenergy.com/news-events/events.
About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.
Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include patented KRONOS MMR ™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), 'ZEUS', a solid core battery reactor, and 'ODIN', a low-pressure coolant reactor, and the space focused, portable LOKI MMR ™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.
Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America.
HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.
NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR ™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.
For more corporate information please visit: https://NanoNuclearEnergy.com/
For further NANO Nuclear information, please contact:
Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206
PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM
Cautionary Note Regarding Forward Looking Statements
This news release, the conference presentation referred to herein, and statements of NANO Nuclear's management in connection with this news release and such presentation contain or may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'potential', 'will', 'should', 'could', 'would' or 'may' and other words of similar meaning. In this press release and the related presentation, forward-looking statements may include those related to NANO Nuclear's development, demonstration and regulatory licensing plans and goals, as well as the anticipated future benefits to NANO Nuclear of being a publicly traded company. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy ('DOE') or related state or non-U.S. nuclear fuel licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the U.S. Nuclear Regulatory Commission, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
authID Revenue Jumps 367% in Q2
Key Points Record quarterly revenue grew approximately 415.3% year over year in Q2 2025, reaching $1.4 million for the quarter on significant customer momentum. Operating expenses increased approximately 63.9% year over year and a net loss of $4.4 million. Annual recurring revenue metrics and pipeline advanced. These 10 stocks could mint the next wave of millionaires › authID (NASDAQ:AUID), the identity technology firm specializing in privacy-focused biometric authentication, reported its second quarter 2025 results on Aug. 14, 2025. The most significant news in the release was a sharp jump in GAAP revenue to $1.4 million, reflecting substantial customer and booking momentum, even as Operating expenses and net losses continued to climb. There were no analyst estimates with which to compare results. Management highlighted record growth across several metrics, but persistent losses and new credit provisions underlined continued financial challenges. authID's business model and strategic focus authID provides identity authentication solutions, including its biometric platform called PrivacyKey. The platform transforms biometric data -- like facial images -- into cryptographic keys, which allows for quick and highly secure identity verification. Crucially, no actual biometric data is stored, aiding regulatory compliance and privacy. The company's business targets regulated sectors and high-risk transactions that require a high level of authentication assurance. Recent company focus areas include driving technological innovation, broadening its partnership network, and expanding recurring revenue. Key success factors are product leadership, strategic alliances, and effectiveness in converting pilots or trials into long-term contracts. Quarterly review: Revenue growth, metrics, and execution The period saw authID post record GAAP revenue, marking a notable year-over-year increase in GAAP revenue. AuthID also secured a live production trial with a Fortune Global 500 company in the UK, an agreement anticipated to transition into a full contract if successful. The company's annual recurring revenue (ARR, non-GAAP) reached $5.8 million, up from $1.1 million of ARR (non-GAAP) as of Q2 2024 and $1.2 million of ARR (non-GAAP) as of Q1 2025. Gross booked annual recurring revenue (bARR, non-GAAP) jumped to $2.2 million from $0.63 million in Q2 2024. Net bARR (non-GAAP), which subtracts the value from contracts delayed or lost, grew to $1.9 million. The company's remaining performance obligation (RPO), which shows the contracted but not yet recognized revenue, was $13.8 million.—more than triple the figure from Q2 2024. On the technology side, authID launched IDX, a new biometric authentication product developed in partnership with NEC, a provider of biometric hardware. Management claims this product enables ultra-fast and accurate authentication for regulated industries, while maintaining customer privacy. The period also featured enhancements to the PrivacyKey product, now capable of one-to-many search -- meaning it can identify a person out of a large group quickly -- without the need to store any biometric data. Strategic partnerships played a role in the quarter's results. Alongside NEC, management highlighted a new agreement with Prove, which operates a large-scale identity fraud platform. These partnerships are intended to enable faster market entry and broaden the user base, particularly by embedding authID's solutions into third-party ecosystems. In addition, the company expanded its board with new members and advisors, aiming to support ongoing growth and value creation for stakeholders. Operating expenses increased approximately 63.9% year-over-year, totaling $5.9 million, primarily reflecting investments in hiring, sales, and research and development. The company cited a $0.8 million provision for estimated credit losses, which reflects new assessments around credit risk for certain customer contracts. These expense increases, along with persistent net losses, highlight the pressure of scaling operations ahead of realized revenue. Notably, net loss (GAAP) widened to $4.4 million, compared to $3.3 million for Q2 2024. Net cash flows from operations (GAAP) showed an outflow of $8.4 million for the first half of 2025, with $8.3 million in cash on hand at the end of the quarter. Share count increased, reaching 13.2 million on a diluted basis versus 9.5 million a year ago. There were also challenges during the period. AuthID had to book new credit loss provisions, signaling some delays or potential issues with collecting revenue on certain customer contracts. Some signed deals faced slowdowns moving from contract to full go-live, impacting recognized bARR (non-GAAP) and creating challenges on the path toward more predictable recurring revenue. Throughout the quarter, the company continued to emphasize its privacy-by-design approach. Compliance with privacy and biometric regulations is a key selling point, especially for large enterprises and public sector clients. There were no new regulatory hurdles cited for the period, but the continued assertion that the platform stores no biometric data is a core strategic differentiator. Looking ahead: Outlook and potential risks Management did not provide specific forward-looking financial guidance for revenue, margin, or profit for upcoming quarters or the full year. In public commentary earlier in the year, management referenced a bookings target of $18 million in gross bARR (a non-GAAP measure) for fiscal 2025. With half-year bARR (non-GAAP) totaling $2.2 million for the first six months of 2025, achieving this full-year goal would require a significant acceleration in booking large contracts and ramping deployments in the next two quarters. For investors and stakeholders, areas to observe in coming quarters include the pace of contract conversions, expense management, success of partnership-driven sales, and resolution of credit risk exposures. Given the persistent high operating costs and net losses, the company's ability to demonstrate path to sustained profitability and positive cash flow remains a critical watchpoint. AUID does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Iqstel Margin Jumps 7%
Key Points Gross margin rose by 7.65 percentage points year over year for the six months ended June 30, 2025, supporting improved profitability. Shareholder equity was $14.29 million, reflecting a stronger balance sheet. These 10 stocks could mint the next wave of millionaires › Iqstel (NASDAQ:IQST), a diversified global telecommunications and technology services provider, reported earnings on Aug. 14, 2025. Shareholder equity stood at $14.29 million. The quarter saw the company surpass analyst forecasts, with GAAP revenue of $155.15 million exceeding the analyst estimate of $70.34 million and continuing to strengthen its financial standing, supported by organic growth in its core telecom business. Company Overview and Strategic Focus Iqstel is a provider of international voice, SMS, and fiber-optic connectivity services to businesses and telecom carriers. Its operations span 21 countries and are organized mainly around its telecommunication division, with efforts to diversify into other technology sectors. The company's business has focused on growth in its core telecommunications services while developing new offerings in artificial intelligence (AI), fintech solutions (financial technology products like payment and remittance platforms), and electric vehicles. The telecom segment, which provides services such as VoIP (voice over internet protocol), continues to generate the bulk of revenue, while product innovation and strategic acquisitions remain key to Iqstel's expansion plans. Success in these newer areas depends on realizing growth in high-potential technology markets and integrating new acquisitions effectively. Second Quarter Developments and Performance The main story was continued organic growth in the core telecom segment. All reported revenue increases were organic, with no impact from acquisitions or one-off gains for the six months ended June 30, 2025. The company noted its current revenue mix is 80% telecom and 20% fintech. Subsidiaries such as Etelix, SwissLink Carrier, and Whisl Telecom drive this business, focusing on wholesale voice traffic. However, a detailed breakdown between voice and messaging was not provided for the quarter. Financially, the telecom division delivered net income of $321,321, a 29.9% increase from $247,288 in Q1 2025. Adjusted EBITDA (non-GAAP) across operating businesses reached $1.1 million for the first six months of 2025, with management pointing to expected acceleration in the back half of the year. Gross margin improved by 7.65 percentage points year over year for the six months ended June 30, 2025. The company's fintech and emerging technology segments, which include financial services for cross-border money movement and new AI platforms, remain a small part of the revenue base, collectively making up about 20% of revenue for the first half of 2025. Key developments included preliminary launches of AI product families, such as (for digital customer support) and new partnerships for AI-driven cybersecurity. Strategic acquisitions are a stated priority, with management continuing to pursue new deals, especially in cybersecurity, but no new transactions closed during the period. Capital structure developments were also notable. Shareholder equity reached $14.29 million. Shareholder equity increased from $11.9 million at December 31, 2024, to $14.29 million at June 30, 2025. This improvement came even as the company issued new shares totaling approximately $3.6 million in conversion value during May–June 2025; the market absorbed these without material share price declines, according to management. Assets per share stood at $17.41, while shareholder equity per share reached $4.08 at June 30, 2025, up from $3.37 per share at June 30, 2024. There was no update on workforce expansion, with headcount stable at 100 employees across all divisions. Outlook and What to Watch For the second half of fiscal 2025, management projects revenue of $210 million for the second half, supported by strong preliminary July revenue results of $35 million. If achieved, this would set the company on a $400 million annualized revenue run rate by year-end, with a $340 million revenue target for FY2025. The company continues to target a $15 million annualized Adjusted EBITDA (non-GAAP) run rate, which would require significant growth from the current $1.1 million adjusted EBITDA figure for the first half. No explicit forward guidance on per-share earnings was provided in the release. Leadership did not announce any dividend. Investors and analysts will be monitoring the pace of telecom segment growth, concrete progress in newer technology product families, and any material mergers or acquisitions that could alter the revenue mix. Capital management remains an area to watch, particularly in light of ongoing share issuances tied to the company's growth initiatives. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
4 hours ago
- Globe and Mail
Profound Medical Posts Wider Loss in Q2
Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
